SCHEMBL2748635

SCHEMBL2748635

COCCN(CCOC)C(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4s3)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.48
CDK2 P24941 1/20 0.48
MKNK1 Q9BUB5 1/20 0.48
MKNK2 Q9HBH9 1/20 0.48
ATR Q13535 2/20 0.47
FYN P06241 5/20 0.44
CHEK2 O96017 2/20 0.44
CHEK1 O14757 1/20 0.44
MAPT P10636 5/20 0.42
TP53 P04637 3/20 0.42
PRKD3 O94806 1/20 0.42
PRKD1 Q15139 1/20 0.42
PRKD2 Q9BZL6 1/20 0.42
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAP4K4 O95819 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748893 0.85 MKNK2 (0.64) CDK1CDK2MKNK1MKNK2FYN
SCHEMBL2750376 0.84 ATR (0.54) CDK1CDK2MKNK1MKNK2ATR
SCHEMBL2747417 0.84 CDK8 (0.49) CDK1CDK2MKNK1MKNK2FYN
SCHEMBL2748849 0.82 CDK8 (0.50) CDK1CDK2MKNK1MKNK2FYN
SCHEMBL2747422 0.82 MAP4K4 (0.58) CDK1CDK2MKNK1MKNK2ATR
SCHEMBL2750278 0.82 MAPK1 (0.43) MAPTPOLB
SCHEMBL2750253 0.81 FYN (0.54) CDK1CDK2MKNK1MKNK2ATR
SCHEMBL2749719 0.81 MAPK1 (0.46) MAPTRXFP1
SCHEMBL2748906 0.81 PRKD3 (0.62) CDK1CDK2MKNK1MKNK2FYN
SCHEMBL2750800 0.80 PRKD3 (0.54) CDK1CDK2MKNK1MKNK2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 CDK1 298/4885CDK2 191/4885MKNK1 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.